Zhejiang Doer Biologics Co., Ltd.

8 clinical trials · Sponsor

Record	Firm	Date
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia (NCT07693777)	Zhejiang Doer Biologics Co., Ltd.	2026-08-17
A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia (NCT07680829)	Zhejiang Doer Biologics Co., Ltd.	2026-08-01
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects (NCT07024212)	Zhejiang Doer Biologics Co., Ltd.	2025-04-22
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer (NCT07056777)	Zhejiang Doer Biologics Co., Ltd.	2025-03-25
A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia (NCT06555640)	Zhejiang Doer Biologics Co., Ltd.	2024-08-01
A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624 (NCT05378893)	Zhejiang Doer Biologics Co., Ltd.	2022-06-22
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (NCT05639153)	Zhejiang Doer Biologics Co., Ltd.	2022-05-13

Every clearance here is in the API, with alerts when new ones post.